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Interventions
Patients presenting for invasive cardiovascular procedures are frequently taking a variety of medications aimed to treat
risk factors related to heart and vascular disease. During the procedure, antithrombotic, sedative, and analgesic medica-
tions are commonly needed, and after interventional procedures, new medications are often added for primary and sec-
ondary prevention of ischemic events. In addition to these prescribed medications, the use of over-the-counter drugs and
supplements continues to rise. Most elderly patients, for example, are taking 5 or more prescribed medications and 1 or
more supplements, and they often have some degree of renal insufﬁciency. This polypharmacy might result in drug–drug
interactions that affect the balance of thrombotic and bleeding events during the procedure and during long-term treat-
ment. Mixing of anticoagulants, for instance, might lead to periprocedural bleeding, and this is associated with an in-
crease in long-term adverse events. Furthermore, the range of possible interactions with thienopyridine antiplatelets is of
concern, because these drugs are essential to immediate and extended interventional success. The practical challenges in
the ﬁeld are great—some drug–drug interactions are likely present yet not well understood due to limited assays,
whereas other interactions have well-described biological effects but seem to be more theoretical, because there is little
to no clinical impact. Interventional providers need to be attentive to the potential for drug–drug interaction, the associ-
ated harm, and the appropriate action, if any, to minimize the potential for medication-related adverse events. This re-
view will focus on drug–drug interactions that have the potential to affect procedural success, either through increases
in immediate complications or compromising longer-term outcome. (J Am Coll Cardiol Intv 2012;5:1195–208) © 2012 by
the American College of Cardiology FoundationR
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tPolypharmacy is commonplace: over 80% of elderly pa-
tients, for example, take at least 1 prescribed medication,
and over one-half take 5 or more prescription drugs together
(1). This has important implications in the setting of
percutaneous coronary intervention (PCI) because drug–
drug interactions (DDI) might affect the balance of pre-
venting periprocedural thrombotic events such as myocar-
dial infarction versus the potential for increasing bleeding.
Drug–drug interactions can primarily be classified as either
pharmacokinetic (where 1 drug affects the absorption, dis-
tribution, metabolism, or elimination processes of another)
or pharmacodynamic (where pharmacokinetic properties are
unchanged, but the effects of a drug are either exaggerated
or diminished). Although many combinations of medica-
tions can be safely used together, at least 1 analysis of a
claims database has estimated the risk of exposure to a
clinically meaningful drug interaction to be in excess of
6%/year (2). Given the high incidence of cardiovascular
disease and the use of multiple drugs during and after PCI,
DDI that might affect procedural or late outcomes are very
important. This review examines potential DDI in the
periprocedural term of PCI.
Drug–drug interactions can be difficult to identify. Al-
though altered concentrations of drugs can be objectively
measured for most medications in research settings, it is
more difficult to describe the clinical impact. Often, there iare very few data about the clinical effects of sub- or
supra-therapeutic concentrations of drugs in humans. Ad-
ditionally, commercial bioassays are only available for se-
lected medications, making many DDI “theoretical” or
reliant on presentation of clinical sequelae before suspicion
is raised. In contrast, some DDI produce measurable phar-
macokinetic or pharmacodynamic changes, but these have
little effect on clinical outcomes. Large-scale, prospective
clinical assessments examining the impact of DDI are rare.
Although drugs in development are tested in combination
with commonly prescribed medications for the particular dis-
ease state, such assessments are limited. Rather, many DDI
are retrospectively identified and described via case reports
or case series. These issues lead to difficulty in determining
causality or whether a DDI is clinically meaningful in practice. To
aid in this process, several scoring systems have been developed.
Austin Bradford-Hill criteria, developed to determine association
with causality, have been applied to studies of potential DDI (3).
ecently, the Drug Interaction Probability Scale (Table 1) has
een developed to more specifically address causality of a DDI
ith a clinical adverse event (4).
Although the possibility of multiple DDI exists with the
edication regimen of any patient when presenting for a
ardiac intervention, this review will focus on DDI that have
he potential to affect procedural outcomes, either through
ncreases in procedural complications or compromising
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1197longer-term procedural success. A brief discussion of other
DDI that are highly likely in a patient with coronary artery
disease is also provided.
Anticoagulants
Anticoagulants (e.g., heparins and direct thrombin inhibi-
tors) in combination with antiplatelet therapies remain the
standard of care to minimize thrombotic complications in
acute coronary syndromes and PCI. Most DDI with anti-
coagulant therapies are pharmacodynamic. There are mul-
tiple anticoagulants available with many targets in the
coagulation cascade, potentially exposing the patient to
increased bleeding complications (Table 2). Likewise, sev-
eral oral anticoagulants are now available that can affect
periprocedural events as well as long-term outcome.
Oral Anticoagulants at the Time of PCI
Oral anticoagulation with vitamin K antagonists (e.g.,
warfarin) is often administered to patients with cardiovas-
cular disease. Although the exact frequency is uncertain, it is
estimated that approximately 5% percent of all patients
undergoing PCI are receiving chronic anticoagulation ther-
apy (5). Warfarin depletes vitamin K-dependent clotting
factors II, VII, IX, and X, which is a broader impact than
most anticoagulants used during PCI (Factors Xa and IIa).
This combination of broad-target factor-depleting drugs
and potent inhibitors of activated factors can markedly
increase the bleeding risk.
The outcomes among warfarin-treated patients undergo-
ing PCI have been evaluated in both single and multicenter
registries and trials with variable results. The National
Cardiovascular Data Registry database revealed that 3.6% of
patients undergoing PCI were receiving warfarin at the time
of the procedure (6). Increases in in-hospital bleeding
(elective PCI: 3.2% vs. 1.9%, adjusted odds ratio [OR]:
1.26, 95% CI 1.09 to 1.46; urgent PCI: 8.2% vs. 4.8%,
adjusted OR: 1.42, 95% CI 1.14 to 1.76) were observed,
compared with patients not receiving warfarin. Differences
in unadjusted in-hospital mortality (elective PCI: 1.4% vs.
0.6%, p  0.001; urgent PCI: 8.6% vs. 4.5%, p  0.001)
were also observed. Similarly, an analysis of the CRUSADE
(Can Rapid risk stratification of Unstable angina patients
Suppress ADverse outcomes with Early implementation of
the ACC/AHA guidelines) registry, a voluntary, observa-
tional registry designed to improve the care of patients with
unstable angina and non–ST-segment elevation myocardial
infarction, revealed that those patients receiving warfarin
were less likely to undergo PCI (36.8% vs. 51.8%, adjusted
OR: 0.80, 95% CI 0.75 to 0.86) and also less likely to
receive important antiplatelet therapies, such as aspirin
(90.6% vs. 95.9%, adjusted OR: 0.52, 95% CI 0.46 to 0.57)
and clopidogrel (37.7% vs. 55.6%, adjusted OR: 0.53, 95%CI 0.50 to 0.56) (7). These patients also had delayed time to
PCI. Warfarin-treated patients had increased rates of blood
transfusions (13.2% vs. 9.0%, adjusted OR: 1.09, 95% CI
1.00 to 1.19) and substantially increased rates of major
bleeding (13.8% vs. 9.0%, adjusted OR: 1.88, 95% CI 1.48
to 2.38) when receiving co-administration of glycoprotein
IIb/IIIa inhibitors.
Because of bleeding concerns, caution is needed for
patients being treated with warfarin who present for PCI,
although there are limited evidence-based data. Guidance
suggests the International Normalized Ratio (INR) should
be 1.8 for femoral cases and that patients with therapeutic
INRs should generally have elective PCI procedures delayed
until the INR falls to within this level (8). However, given
the urgent/emergent nature of
many coronary interventions,
this might not be acceptable.
Although reversal of INR is pos-
sible, it might take 12 to 24 h
after the administration of phy-
tonadione (vitamin K), and full
reversal is generally not advis-
able, because resistance to anti-
coagulation has been demon-
strated upon re-initiation of
warfarin in vitamin K-treated
patients. Administration of
periprocedural fresh frozen
plasma or other factor products
is also an option, but this might
be impractical in an emergency
intervention and is only effective
for a limited time frame. Re-
gardless, patients receiving oral
anticoagulants should be identi-
fied before the procedure, if pos-
sible, and a strategy should be
developed to minimize both
bleeding risks from the procedure
and thrombotic risk from lack of
this drug therapy. An important strategy is the use of the radial
artery to decrease bleeding risk, although the INR is not
recommended to exceed 2.2 for these cases (8).
Recently, new oral anticoagulants have been approved for
use in humans that specifically target either Factor IIa
(dabigatran) or Factor Xa (apixaban, rivaroxaban). To date,
no definitive evaluation of the efficacy or safety of these
drugs in the setting of PCI has been performed. However,
the use of rivaroxaban in acute coronary syndromes (ACS)
patients has been evaluated in the ATLAS-2 (Anti Xa
Therapy to Lower cardiovascular events in addition to
standard therapy in subjects with Acute Coronary Syn-
drome) trial, whereupon 2.5- and 5-mg twice daily dosing
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
AUC  area under the curve
CCB  calcium channel
blocker
COX  cyclooxygenase
DDI  drug–drug
interactions
DHP  dihydropyridine
FDA  U.S. Food and Drug
Administration
GI  gastrointestinal
INR  International
Normalized Ratio
NSAID  nonsteroidal anti-
inflammatory drug
PCI  percutaneous
coronary intervention
PPI  proton pump inhibitor
UFH  unfractionated
heparinregimens (9) in addition to standard therapy after revascu-
 dou
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 2 , 2 0 1 2
D E C E M B E R 2 0 1 2 : 1 1 9 5 – 2 0 8
Dunn et al.
Drug–Drug Interactions in PCI
1198larization procedures reduced the risk of ischemic events
and increased the risk of bleeding events. Several other
studies of Factor Xa inhibitors have been discontinued due
to excessive bleeding. Therefore, at present, elective PCI
should not be performed during exposure to these newer
agents and should be delayed in a time frame consistent
with the pharmacological offset of each agent (Table 2).
Optimal reversal strategies for urgent or emergent proce-
dures in patients receiving these medications have not been
determined.
Parenteral Anticoagulants at the Time of PCI
During the treatment of ACS, patients might be transi-
tioned from one anticoagulant strategy to another. This can
Table 1. Elements of the Drug Interaction Probability Scale
Factor
Previous credible reports of the interaction in humans
Observed interaction consistent with interactive properties of precipitant drug
Observed interaction consistent with interactive properties of object drug
Event consistent with the known or reasonable time course of the interaction (onset
Interaction remitted upon dechallenge of the precipitant drug with no change in th
Interaction reappeared when the precipitant drug was re-administered in the presen
use of object drug
Reasonable alternative causes for the event
Object drug detected in the blood or other ﬂuids in concentrations consistent with
interaction
Drug interaction conﬁrmed by objective evidence consistent with the effects on the
Interaction greater when the precipitant drug was increased or less when precipitan
decreased
See Horn et al. (4). *Total score8 highly probable; 5 to 8 probable; 2 to 4 possible; and2
Table 2. Characteristics of Anticoagulants Used in Patients Undergoing Ca
Medication Mechanism of Action
Approxim
Pharmacologi
Apixaban Direct factor Xa inhibitor Oral: 3–4 h
Argatroban Direct thrombin inhibitor Bolus: immedia
(no bolus): 2
Bivalirudin Direct thrombin inhibitor Bolus: immedia
(no bolus): 2
Dabigatran Direct thrombin inhibitor Oral: 1–2 h
Enoxaparin Low-molecular weight heparin;
cofactor for antithrombin
inhibition of primarily factor Xa
Intravenous: im
Subcutaneou
Fondaparinux Co-factor for antithrombin
inhibition of factor Xa
Intravenous: im
Subcutaneou
Heparin (unfractionated) Co-factor for antithrombin
inhibition of factor IIa and Xa
Bolus: immedia
(no bolus): 6
Rivaroxaban Direct factor Xa inhibitor Oral: 2–4 hbe problematic, leading to unpredictable “stacking” of anti-
coagulant effects due to differences in pharmacokinetics and
drug clearance among anticoagulants. The reasons that
“anticoagulant mixing” or “anticoagulant crossover” occurs
are multiple and understandable, because numerous effective
agents and combinations are available. There are valuable
data on the frequency and clinical impact of anticoagulation
mixing in patients with ACS and PCI. The SYNERGY
(Superior Yield of the New Strategy of Enoxaparin, Revas-
cularization and Glycoprotein IIb/IIIa inhibitors) trial,
which compared enoxaparin and unfractionated heparin
(UFH) in the medical treatment of ACS undergoing an
early interventional approach (10), demonstrated increased
rates of bleeding with crossover, regardless of whether
Score* Assigned If Yes Score* Assigned If No†
1 1
1 1
1 1
r offset) 1 1
ct drug 1 2
continued 2 1
1 1
posed 1 0
drug 1 0
1 1
btful. †If unknown or not applicable, 0 points are assigned.
Catheterization
set
Approximate
Pharmacological Offset Clinical Considerations
24 h Hepatic and/or renal dysfunction will
prolong elimination
sion 2–4 h Hepatic dysfunction will prolong elimination
sion 2 h Renal dysfunction will prolong elimination
24–48 h Renal dysfunction will prolong elimination
te
h
12 h Renal dysfunction will prolong elimination
te
h
24 h Renal dysfunction will prolong elimination
Doses recommended for acute coronary
syndromes do NOT result in therapeutic
anticoagulation, and combination
therapy with heparin is recommended
for interventional procedures
sion 4–6 h
24 h Hepatic and/or renal dysfunction willand/o
e obje
ce of
the pro
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t drugrdiac
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cal On
te Infu
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te Infu
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1199patients crossed from UFH to enoxaparin or vice versa (11).
Mixing strategies with enoxaparin were prospectively tested
in the STACKENOX (STACK-on to ENOXaparin)
study, where 72 healthy subjects who were receiving enoxa-
parin were randomized to UFH 4, 6, or 10 h after the last
dose of enoxaparin (12). Anti-Xa activity was increased at
all time-points, suggesting longer duration of discontinua-
tion is warranted when attempting to switch patients from
enoxaparin to UFH. Other anticoagulant strategies suggest
crossovers have less relevant impact on clinical outcomes.
The ACUITY (Acute Catheterization and Urgent Inter-
vention Triage strategY) trial of ACS patients undergoing
PCI demonstrated no change in ischemic endpoints when
patients were crossed over from UFH or enoxaparin to
bivalirudin (13). In contrast, there was approximately a 50%
reduction in major bleeding events among patients switched
to bivalirudin. Furthermore, patients in the OASIS-5 (The
Fifth Organization to Assess Strategies in Acute Ischemic
Syndromes) trial receiving fondaparinux were recommended
to receive UFH at the time of PCI due to an early excess in
procedural thrombotic complications (14). This approach
has also been suggested by guidelines (15). Table 2 illus-
rates various anticoagulants that might be used in the
eriprocedural setting, their mechanism of action, and
nset/offset of action.
Guidelines have generally recommended maintaining an-
icoagulant consistency throughout the ACS- to -PCI
pectrum (15), due mainly to the adverse clinical effects of
nticoagulant crossover demonstrated in the SYNERGY
rial. As mentioned in the preceding text, a notable excep-
ion to this is the therapeutic benefit of adding UFH to
atients undergoing PCI being treated with fondaparinux.
lthough some data suggest that switching anticoagulants
an be done safely, this should occur in a systematic way
Table 2).
ntiplatelets and Oral Anticoagulants After PCI
Patients undergoing PCI often have indications for long-
term oral anticoagulant therapy with warfarin derivatives.
The combination of warfarin with oral antiplatelet therapy
after PCI has been associated with increased rates of
bleeding, despite the medical necessity of both therapies.
Andreotti et al. (16), in a meta-analysis of 10 studies with
7,836 patients receiving aspirin plus warfarin versus those
receiving warfarin alone after ACS, demonstrated that
combination therapy (warfarin plus aspirin) was associated
with increased rates of major bleeding events compared with
aspirin only (OR: 2.32, 95% CI 1.63 to 3.29). The problem
is compounded further because most post-PCI patients
receive aspirin and thienopyridines after stent implantation.
The risk of triple therapy was evaluated by Mattichak et al.
(17), where 40 patients receiving triple therapy were com-
pared with 42 patients receiving standard dual antiplatelettherapy (aspirin plus clopidogrel) after PCI. A trend in
increased bleeding (15% vs. 9%) and an increase in the
number of transfusions were seen in patients receiving triple
therapy. Khurram et al. (18) and Rogacka et al. (19) also
observed an increase in bleeding events after PCI in patients
receiving triple therapy versus dual antiplatelet therapy.
Conversely, an analysis of the GRACE registry (Global
Registry of Acute Coronary Events) of 580 patients receiv-
ing triple therapy revealed no overall increase in the risk of
major bleeding events between warfarin plus dual antiplate-
let therapy versus warfarin plus single antiplatelet therapy
(5.9% vs. 4.6%, p  0.46) (20). In fact, reductions in the
incidence of ischemic stroke were observed with triple
therapy versus dual antiplatelet therapy (0.7% vs. 3.4%,
respectively, p  0.02).
Overall, observational evidence with regard to the risk of
bleeding events prompted more formal guidance from the
American College of Cardiology in 2009, when several
strategies were promoted that were designed to minimize
the bleeding risk when dual antiplatelet therapy and warfa-
rin must be used together (21). These include minimizing
the aspirin dose to 75 to 81 mg daily, lowering the INR goal
to 2.0 to 2.5 (depending on the indication for anticoagula-
tion), and prophylactic use of gastroprotective strategies,
including proton pump inhibitors (PPIs). However, clini-
cians should be cautious and avoid exposure to “triple
therapy” if possible, including re-evaluation of the indica-
tions for both antiplatelet therapy and warfarin. In addition,
it might be prudent to avoid scenarios in which long-term
dual antiplatelet therapy is routinely administered in pa-
tients with chronic indications for anticoagulation (e.g.,
drug-eluting stent placement). The use of PPIs in patients
receiving clopidogrel is controversial, as discussed in the
following text. No formal evaluation of more potent P2Y12
inhibitors (e.g., prasugrel, ticagrelor) in combination with
oral anticoagulants has occurred, adding more uncertainty
to the risk of bleeding when these agents are employed.
Antiplatelets
Aspirin. Aspirin, along with P2Y12-inhibitor therapy, is
essential in the maintenance of stent patency and in the
primary and secondary prevention of myocardial infarction.
Drug–drug interactions with aspirin primarily exist in the
form of pharmacodynamic interactions based on overlap-
ping anti-hemostatic mechanisms. However, some interac-
tions where aspirin effectiveness can be altered have been
promoted, primarily through the competitive inhibition of
the acetylation site of cyclooxygenase (COX) in the platelet.
Although aspirin does have nonsteroidal anti-inflammatory
(NSAID) properties, its use as an analgesic is limited due to
excessive adverse gastrointestinal (GI) events at higher
doses. Therefore, traditional NSAIDs, such as ibuprofen
and naproxen, and COX-2 selective agents, such as cele-
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1200coxib, are likely to be used in addition to aspirin in patients
who require chronic analgesic control, particularly those
with osteoarthritis. Additionally, NSAID therapy might be
used in the setting of pericarditis to reduce inflammation,
which might occur in post-interventional patients after
acute myocardial infarction. Because the antiplatelet effect
of aspirin is dependent on adequate inhibition of COX-1, it
is theoretically possible that competitive inhibition of
COX-1 by other NSAIDs might lessen the antiplatelet
efficacy of aspirin, particularly non–COX-2 selective agents.
A randomized, prospective, open-label, crossover study
demonstrated that the antiplatelet effect of aspirin was
significantly diminished when 400 mg of ibuprofen was
administered 2 h before 81 mg of aspirin (22). In this study,
patients received 6 consecutive days of aspirin (81 mg)
administered 2 h before ibuprofen (400 mg) followed by a
2-week washout, followed by the same regimen but with the
reversed administration (ibuprofen 2 h before aspirin ad-
ministration). Serum thromboxane B2 levels measured 24 h
fter study drug administration on Day 6 were maximally
educed in the patients receiving aspirin before ibuprofen
mean percentage inhibition: 99  0.3 [SD]) but were only
oderately reduced when ibuprofen was taken before aspi-
in (mean percentage inhibition: 53  7 [SD]) (p  0.001).
nother prospective trial evaluating the antiplatelet effect of
spirin in both ibuprofen- and celecoxib-treated patients
dentified that ibuprofen-treated patients had significantly
igher levels of platelet aggregation compared with patients
ot receiving ibuprofen (23). Additionally, a retrospective
ohort evaluation of 7,107 aspirin-treated patients identified
hat patients taking ibuprofen had a higher risk of all-cause
ortality compared with nonusers (hazard ratio: 1.93, 95%
I 1.30 to 2.87, p  0.0011) (24). On the basis of these
ata, the American Heart Association issued a Scientific
dvisory in which they suggest that this interaction might
e clinically significant (25). The U.S. Food and Drug
dministration (FDA) further recommended separating the
iming of administration of aspirin such that it is taken 30
in before the receipt of ibuprofen or 8 h after the dose
26). The effects of NSAIDs on COX are reversible, such
hat the molecule releases from the binding site after the 8-h
ime frame post-administration. However, this dosing sug-
estion would only apply to non–enteric-coated aspirin
roducts. No specific recommendation regarding timing of
nteric-coated aspirin products—which purposefully delay
bsorption—is provided. Catella-Lawson et al. (22) dem-
nstrated that the antiplatelet effect of aspirin is attenuated
f ibuprofen is administered up to 12 h after enteric-coated
spirin administration. Data are less clear with other
SAIDs but are suggestive in total that nonselective
SAIDs (e.g., indomethacin, naproxen) also interfere with
he antiplatelet effects of aspirin in a similar manner as
buprofen, whereas use of more COX-2 selective agentse.g., celecoxib, diclofenac, meloxicam) likely do not inter-
ere with aspirin (27–29).
Thienopyridine P2Y12 inhibitors. Thienopyridines, including
iclopidine, clopidogrel, or prasugrel, are uniformly used for
variable duration in all patients undergoing stent implan-
ation and in an increasing number of patients treated
edically for ACS. Therefore, DDI affecting the efficacy or
afety of thienopyridines have tremendous implications.
Many theoretical DDI with thienopyridines involve
harmacokinetic interactions that interfere with the meta-
olic conversion of the parent compound to the active
etabolite. Thienopyridines are prodrugs, requiring conver-
ion by the liver via the CYP450 system before the desired
linical effect is achieved. Clopidogrel requires a 2-step
onversion with an intermediate metabolite via some com-
ination of CYP3A4, 1A2, 2C9, 2C19, and 2B6 (30).
rasugrel has a more simplified metabolism, requiring only
1-step conversion via CYP3A4 and 2B6 (31). The precise
ontribution of each isoenzyme and what, if any, compen-
atory changes might take place have been difficult to assess
n vivo, given that the active metabolite is unstable and
ifficult to measure. Drugs that interfere with or are
o-metabolized through that particular metabolic pathway
ight decrease the antiplatelet effect of thienopyridines and
xpose the patient to increased risk of thrombotic events.
PPIs. Proton pump inhibitors—including omeprazole, lan-
soprazole, pantoprazole, rabeprazole, and esomeprazole—
are widely used in the treatment and prevention of acid-
related GI disorders. They are among the most widely used
drugs in the world and are also recommended as first-line
protective therapy against drug-induced gastric erosion and
bleeding events with dual antiplatelet therapy (32). How-
ever, PPIs also have varying affinity and inhibitory proper-
ties of the isoenzyme CYP2C19, which might theoretically
reduce biotransformation to the active metabolite and in-
crease the risk of clinical events. Interference with the
antiplatelet effects of clopidogrel by the concomitant use of
PPIs has been suggested in multiple clinical trials (33–36).
Data regarding the clinical significance of a thienopyridine–
PPI interaction seem to be mixed. Many (37–39) but not all
(40,41) observational studies of registries or claims data
seem to indicate risk with co-administration, but such data
might be at risk of confounding bias or more subject to
methodological error. Analyses of randomized controlled
clinical trials have been more uniform in demonstrating no
significant clinical impact of PPI use on the clinical benefit
seen with thienopyridines. An analysis of the TRITON
(Therapeutic Outcomes by optimizing platelet InhibitioN
with prasugrel) study demonstrated that PPI use had no
clinical impact on the efficacy or safety of prasugrel or
clopidogrel (35). Additionally, a prospective randomized
controlled trial of a novel dosage formulation (CGT-2168)
evaluated clopidogrel and omeprazole versus placebo in the
COGENT-1 (Clopidogrel and the Optimization of Gas-
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Although the study was primarily designed to examine GI
safety endpoints, cardiovascular events were also identified,
although the study was not adequately powered to measure
these events. The study was terminated prematurely due to
lack of funding, and the mean follow-up period was only
133 days. Overall, the study showed no significant difference
between omeprazole and placebo in ischemic outcomes, and
GI safety outcomes favored the combination product of
clopidogrel and omeprazole. Although the COGENT-1
trial represents the strongest data to date that the interaction
between clopidogrel and PPIs is not clinically significant,
limitations such as potential differences in release kinetics, a
relatively short follow-up, and that the trial was not primar-
ily designed to address cardiovascular safety make this a
continued source of controversy. Recently, the American
College of Cardiology Foundation/American College of
Gastroenterology/American Heart Association released a
consensus statement summarizing evidence regarding the
clopidogrel–PPI interaction and recommended that a care-
ful assessment of the risk-benefit profile of the patient with
regard to GI bleeding and cardiovascular event risk take
place. In addition, PPIs might still be recommended in
high-risk patients receiving dual antiplatelet therapy (43).
The FDA has also recommended avoiding the concomitant
use of clopidogrel and omeprazole or esomeprazole, despite
the lack of any significant guidance from major cardiovas-
cular organizations (44). Although controversy remains with
regard to this decision, it seems prudent to avoid these
specific combinations at the present time. The use of
pantoprazole or rabeprazole might be considered preferen-
tial for high-risk GI patients requiring the use of clopidogrel
due to their lesser affinity for CYP2C19. The use of certain
histamine antagonists (famotidine, ranitidine) should also be
considered as first-line therapy in preference to PPIs, which are
not metabolized through the CYP450 system. The use of
prasugrel or ticagrelor instead of clopidogrel might also be
considered if a CYP2C19-inhibiting PPI must be used, al-
though this must be weighed against a likely increase in
bleeding risk.
STATINS. The 3-hydroxy-3-methylglutaryl-coenzyme A re-
uctase inhibitors (“statins”) are indicated in virtually every
atient undergoing vascular intervention and would be
ighly likely to be co-administered with clopidogrel. Mech-
nistically, statins were hypothesized to blunt the effect of
lopidogrel due to varying degrees of competitive metabo-
ism through CYP3A4 (45), a known pathway in the
onversion of the clopidogrel parent compound to its active
etabolite. This hypothesis was first examined by Lau et al.
46) in a randomized, controlled trial examining the effects
f increasing atorvastatin doses in clopidogrel-treated pa-
ients on ex-vivo platelet function. The study found that
ncreased atorvastatin doses decreased platelet function in
lopidogrel-treated patients in a linear manner, with dosesf 40 mg and larger completely attenuating the effects of
lopidogrel. However, multiple subsequent pharmacody-
amic studies of the effect of both atorvastatin (47,48) as
ell as other statin drugs (49–51) have identified no effect
f co-administration on ex-vivo mediated platelet function.
nalyses of the CREDO (Clopidogrel for the Reduction of
vents During Observation) (52), CHARISMA (Clopi-
ogrel for High Atherothrombotic Risk and Ischemic
tabilization, Management, and Avoidance) (53), and
ROVE-IT (Pravastatin or Atorvastatin Evaluation and
nfection Therapy-Thrombolysis In Myocardial Infarction
2) trials (54) have demonstrated no impact of statin use on
linical events in clopidogrel-treated patients. On the basis
f these data, there is no suggestion or recommendation to
odify statin therapy in patients receiving clopidogrel or
ther thienopyridines.
CALCIUM CHANNEL BLOCKERS. Calcium channel blockers
(CCBs) are often co-administered in patients being treated with
thienopyridines. It has been speculated that certain CCBs,
which inhibit CYP3A4 (verapamil, diltiazem), might inter-
fere with the biological conversion of clopidogrel to its
active metabolite. This concept has been examined by 2
studies of exvivo mediated platelet function in clopidogrel-
treated patients. Siller-Matula et al. (55) demonstrated that
clopidogrel-treated patients receiving CCB therapy had
higher platelet-reactivity index values than patients not
receiving CCB. These findings were supported by Gremmel
et al. (56) in which clopidogrel-treated patients receiving
CCBs had higher levels of ADP-induced platelet aggrega-
tion compared with patients not receiving a CCB. To date,
only 1 evaluation of the clinical impact of CCB therapy on
the efficacy of clopidogrel has been performed, using pa-
tients enrolled in the CREDO trial. Overall, there was no
significant difference in the 1-year primary composite end-
point of death, myocardial infarction, or stroke in CCB-
treated patients compared with non–CCB-treated patients
(57). On the basis of these findings, there is no recommen-
dation for modification of clopidogrel therapy in patients
receiving a CCB at this time, although more clinical data
are needed for this to be definitive.
AZOLES. Azole antifungal drugs, including ketoconazole,
itraconazole, fluconazole, voriconazole, and posaconazole,
are used in many patients not only to treat fungal infections
but also to prevent fungal infections in high-risk patients.
By nature, these drugs will most likely be co-administered to
patients in short-term courses, with the most common
exception being the need for long-term co-administration
for fungal prophylaxis in a patient who has received an
organ transplant, including heart transplantation. The azole
antifungals inhibit the isoenzyme CYP3A4 (58), although
this can vary within the class, with ketoconazole perhaps
being the strongest inhibitor and fluconazole the most
moderate (59). Ketoconazole in particular is such a strong
inhibitor that it is often used in clinical trials to determine
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CYP3A4-metabolized medications. Because clopidogrel is
partially converted through the CYP3A4 system to its active
metabolite, it has been felt that the azole antifungals might
interfere with this process. In 1 study, ketoconazole co-
administration to clopidogrel-treated patients did indeed
decrease the active metabolite formation of clopidogrel and
attenuate the pharmacodynamic effect on platelet func-
tion but did not affect prasugrel-treated patients (60).
However, there have been no clinical descriptions of
clinical worsening of clopidogrel-treated patients with
azole antifungals. In addition, the impact of more com-
monly used azoles, such as voriconazole and fluconazole,
are unknown. At this time, there is no recommendation
for therapeutic modification of azole antifungals in
thienopyridine-treated patients.
WARFARIN. Warfarin affects a variety of vitamin K-dependent
clotting factors and is also well known for its potential for
DDI. Warfarin is metabolized by multiple cytochrome
P450 enzymes, including both CYP2C9 and CYP3A4,
both of which also are important in the conversion of
clopidogrel to its active metabolite. The potential for
warfarin to interfere with the antiplatelet efficacy of clopi-
dogrel was first identified by Sibbing et al. (61), in which
patients receiving clopidogrel and phenprocoumon were
found to have greater platelet aggregation compared with
patients receiving clopidogrel only. Several observational
studies of clopidogrel and warfarin derivatives have been
performed as well. Most of these studies have examined the
bleeding risk associated with this combination and not
whether the combination is associated with increased
platelet-mediated thrombosis. However, at least 1 large
retrospective analysis of the GRACE registry did not
demonstrate increase bleeding with the combination (20),
which might theoretically be explained by warfarin decreas-
ing the antiplatelet efficacy of clopidogrel. Observational
studies of the ischemic risk of the combination might also
be difficult, due to increased bleeding events resulting in a
high percentage of “supply-demand” types of myocardial
infarctions, which might be difficult to control for in an
observational study. To date, there is no recommendation
for therapeutic modulation on the basis of affecting the
efficacy of clopidogrel, although, as mentioned, several
recommendations have been made with regard to avoidance
of the bleeding effects of the combination of clopidogrel,
aspirin, and warfarin (21).
Non-thienopyridine P2Y12 inhibitors. Ticagrelor is a novel,
on-thienopyridine P2Y12 antagonist recently approved for
use in the setting of ACS-related PCI. Unlike thienopyri-
dines, ticagrelor is not a prodrug and does not require
hepatic metabolism before becoming biologically active.
Ticagrelor is eliminated through the liver, primarily via the
CYP3A4 system. As such, strong CYP3A4 inhibitors (e.g.,
ketoconazole, voriconazole, clarithromycin, protease inhib- eitors) are contraindicated with ticagrelor, because they
might significantly increase exposure to the drug and expose
the patient to toxic effects, such as bleeding (62). Similarly,
strong CYP3A4 inducers (e.g., rifampin, dexamethasone,
phenytoin, carbamazepine) are also contraindicated with
ticagrelor and might result in thrombotic events, such as
stent thrombosis.
Interestingly, aspirin dose seems to be negatively associ-
ated with ticagrelor benefit. In a post hoc analysis of the
PLATO (PLATelet inhibition and patient Outcomes) trial,
the North American cohort failed to show benefit of
ticagrelor over clopidogrel (63). This result has been attrib-
uted to the practice of using higher maintenance doses of
aspirin in the United States. In a multivariate analysis of the
entire PLATO study, aspirin doses 300 mg/day predicted
adverse outcomes in the trial population (hazard ratio: 1.45,
95% CI 1.01 to 2.09). Currently, there is no definitive
biological rationale that explains these findings, but it is
speculated that reductions in platelet-inhibiting prostacy-
clins produced by higher doses of aspirin might blunt the
clinical benefits associated with ticagrelor. Although it is
also entirely possible this interaction represents a chance
finding (64), the FDA has added a boxed warning to the
ticagrelor labeling, recommending limiting the dose of
aspirin to 100 mg/day when used with ticagrelor (62).
Sedatives/analgesics. Conscious sedation modalities are
employed in most interventional settings (8,65). Typically,
this consists of a short-acting intravenous or oral benzodi-
azepine and a short-acting intravenous opiate. Although
this combination is therapeutically advantageous, it might
also represent a potentially adverse pharmacodynamic DDI
due to the synergistic effects on respiratory depression and
should be applied in a systematic way with appropriate
monitoring of both the level of sedation as well as key safety
indicators, such as cardiac and respiratory function (66). In
addition, benzodiazepines and opiates are extensively me-
tabolized by the liver and are therefore subject to potential
DDI from agents that might affect liver metabolism.
Benzodiazepines. Benzodiazepines used in interventional
rocedures include midazolam, lorazepam, and diazepam.
n general, many of the benzodiazepines are hepatically
etabolized by the CYP450 system to active or inactive
etabolites, especially via CYP3A4 (67). Therefore, classi-
ally “strong” CYP3A4 inhibitors might result in prolonged
r excessive sedation in these patients when used concur-
ently. In addition, several cardiac medications that are
ompetitively metabolized through CYP3A4 have been
pecifically studied with procedural benzodiazepines. Mc-
onnell et al. (68) demonstrated that co-administration of
torvastatin in patients receiving intravenous midazolam
ndergoing general anesthesia resulted in an increase in the
rea-under-the-curve (AUC) and a decrease in the clearance
f midazolam. Although atorvastatin in particular was
xamined in this trial, most CYP3A4-metabolized statins
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In addition, studies of diltiazem and verapamil have also
demonstrated increases in the peak concentration, AUC,
and a decrease in the clearance of intravenous midazolam
(69). A combination of non-dihydropyridine (DHP) CCBs
and midazolam has also been shown to result in more
profound and prolonged sedation than non-exposure to the
interaction (70). Although none of these interactions would
necessarily result in toxic exposure to sedating medications
in the setting of appropriate monitoring, the presence of a
CYP3A4 inhibitor or CYP3A4-metabolized drug might
result in deeper and longer-than-expected sedation periods,
which might potentially expose the patient to risk of severe
respiratory depression. Careful attention to level of sedation
is required when using benzodiazepines in patients receiving
CYP3A4 inhibitors or co-metabolized drugs, and cardiac
catheterization conscious sedation protocols should be con-
servative and provide more frequent monitoring in compar-
ison with other procedural areas. Another alternative would
be to use a nonoxidatively metabolized benzodiazepine (e.g.,
lorazepam) (67), but the longer duration of action might
offset any potential gain reached with avoidance of the DDI.
Opiates. Opiate medications used to relieve pain and facil-
tate sedation during PCI include fentanyl, morphine, and
ydromorphone, among others. The vast majority of opiate
edications are hepatically metabolized through the
YP450 system, and most are hepatically metabolized via
he CYP3A4 isoenzyme (71). Therefore, strong CYP3A4
nhibitors or co-metabolized drugs might increase the level
f sedation and prolong its effects in patients exposed to the
DI, similarly to benzodiazepines. Commonly used cardiac
edications that inhibit CYP3A4 or are metabolized
hrough CYP3A4 include non-DHP CCBs and statin
edications. In particular, non-DHP CCBs have multiple
eports of pharmacokinetic interactions or clinically signif-
cant DDI when administered with fentanyl (70,72). A
areful approach is warranted, like with benzodiazepines,
hen using CYP3A4-altering or metabolized medications
n patients receiving opiates for interventional procedures.
onscious sedation protocols for the catheterization labo-
atory should be conservative and include more frequent
onitoring compared with other procedural areas, given the
ervasive use of statins in the periprocedural setting.
tatins
The potential interaction of statins with clopidogrel therapy
and procedural sedation was discussed previously. However,
statins themselves might be subject to a significant number
of pharmacokinetic DDI, particularly statins that are pri-
marily metabolized by CYP3A4 (atorvastatin, lovastatin,
simvastatin). Inhibition of statin metabolism is likely to
produce an increase in the frequency of muscle-relatedtoxicities, including rhabdomyolysis. Several of these inter-
actions are known to exist in cardiovascular medicine.
Fibrates. Statins and fibric acid derivatives such as gemfi-
brozil, fenofibrate, and fenofibric acid are a potentially
attractive combination of medications to treat mixed dys-
lipidemias and have been used together in practice for some
time. However, increased adverse events have been reported
with this combination. Gemfibrozil specifically seems to
alter statin bioavailability through a multitude of mecha-
nisms— unlike DDI with most statin medications—
including inhibition of statin uptake in the liver through
ATP-cassette binding proteins and organic anion transport-
ers (73). Inhibition of CYP450 enzymes might also play
some role. This interaction results in an increase in statin
concentration independent of the iosenzyme pathway
through which it is metabolized.
Several pharmacokinetic studies of gemfibrozil and various
statins have been performed. Overall, co-administration of
gemfibrozil and statins has resulted in a 185% increase in
the AUC of simvastatin (74), a 35% increase in the AUC of
atorvastatin (75), and an 88% increase in the AUC of
rosuvastatin (76). Clinical data also exist that describe the
adverse impact of this DDI. Several case reports have
described severe adverse effects, such as rhabdomyolysis
with both simvastatin and atorvastatin (77–79). An analysis
of the FDA reporting system revealed 384 reports of
rhabdomyolysis with a statin-fibrate combination, with
most of these (88%) requiring hospital stay for renal failure
(80). Another study evaluating rhabdomyolysis rates in
patients receiving both statins and fibrates found that
gemfibrozil use increased the rate of rhabdomyolysis asso-
ciated with statins by 1 to 2 orders of magnitude compared
with monotherapy (81).
Regulatory bodies and professional societies have ex-
pressed caution with the concomitant prescription of a
statin and a fibrate due to these findings. When using
gemfibrozil with a statin, a maximum dose of 10 mg/day of
rosuvastatin and a maximum of 20 mg/day with lovastatin is
recommended (82,83). Furthermore, the use of simvastatin
and gemfibrozil is now contraindicated after the recent
completion of safety review by the FDA (84). Specific
dosing recommendations are not provided for atorvastatin
or pravastatin, but dose reduction is likely warranted on the
basis of the increases in AUC that have been identified by
pharmacokinetic studies. Lesser alteration of statin concen-
trations has also been shown when paired with fenofibrate
or fenofibric acid, and clinical reports of rhabdomolysis are
significantly lower than those identified with gemfibrozil
(75), suggesting that fenofibrate be preferentially considered
when combination therapy for mixed dyslipidemia is war-
ranted. The use of fluvastatin as the statin of choice might
also be considered, but the reduced potency of that agent
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1204Table 3. Drug–Drug Interactions and Recommended Management in Interventional Cardiology
Drug Interaction Mechanism Recommendation
Oral anticoagulants and procedural
anticoagulants
Pharmacodynamic; potential to inhibit multiple clotting factors and
maintain a minimal level of hemostasis; increases bleeding risk
For elective procedures, hold oral anticoagulant in a
time frame consistent with pharmacological offset
For urgent or emergent procedures, consider use of
hemostatic agents (fresh frozen plasma, factor
products) if necessary; consider radial access as
preferential for cath
Parenteral anticoagulants and procedural
anticoagulants
Pharmacodynamic; potential to inhibit multiple clotting factors and
maintain a minimal level of hemostasis; increases bleeding risk
Maintain consistent use of anticoagulant throughout
ACS to PCI spectrum.
Develop an institution-speciﬁc protocol that allows for
anticoagulant switching to occur in time frames
based on pharmacological and clinical evidence
Dual antiplatelet therapy and oral
anticoagulants
Pharmacodynamic; inhibition of platelet and clotting factor driven
thrombosis; increases risk of bleeding
Evaluate indication for chronic use of both dual
antiplatelet therapy and oral anticoagulant
For warfarin—target INR of 2.0–3.0, use low-dose aspirin
(75–81 mg daily) and consider gastric protection with
PPI No data regarding the risk of bleeding with more
potent P2Y12 inhibitors (prasugrel, ticagrelor) or with
newer oral anticoagulants (apixaban, dabigatran,
Rivaroxaban)
Aspirin and NSAIDs Competitive inhibition of COX-1 might lessen aspirin’s COX-1
mediated inhibition of thromboxane A2 and increase the risk of
thrombotic events
Regular-release aspirin should be administered before
(30 min) or 8 h after nonselective NSAID therapy
(e.g., ibuprofen, indomethacin, naproxen) in patients
receiving continuous NSAID therapy.
Patients receiving COX-2 selective agents (e.g.,
celecoxib, meloxicam, sulindac) likely do not require
altered administration. Consider avoiding the use of
enteric-coated aspirin products in patients receiving
nonselective NSAIDs.
Clopidogrel and PPIs Prevents metabolic conversion of clopidogrel to active metabolite via
inhibition of CYP2C19; might increase risk of thrombotic events,
including stent thrombosis
Avoid concomitant use of clopidogrel with either
omeprazole or esomeprazole
Evaluate indication for PPI therapy. If indicated,
preferentially use pantoprazole or rabeprazole.
Consider histamine-blocker therapy as ﬁrst-line for
reﬂux disease.
Clopidogrel and statins Prevents metabolic conversion of clopidogrel to active metabolite via
competitive metabolism through CYP3A4; might increase risk of
thrombotic events, including stent thrombosis
No recommendation to avoid use or modify therapy if
co-administered
Clopidogrel and calcium channel blockers Prevents metabolic conversion of clopidogrel to active metabolite via
competitive metabolism through or inhibition of CYP3A4; might
increase risk of thrombotic events, including stent thrombosis
No recommendation to avoid use or modify therapy if
co-administered
Clopidogrel and azole antifungals Prevents metabolic conversion of clopidogrel to active metabolite via
inhibition of CYP3A4; might increase risk of thrombotic events,
including stent thrombosis
No recommendation to avoid use or modify therapy if
co-administered
Clopidogrel and warfarin Pharmacodynamic—potential for increased risk of bleeding
Might prevent conversion of clopidogrel to active metabolite via
competitive metabolism through CYP2C9 and CYP3A4 and
increase risk of thrombotic events, including stent thrombosis
See “Dual Antiplatelet Therapy and Oral Anticoagulants”
section for recommendations regarding reducing the
risk of bleeding if co-administration necessary.
No speciﬁc recommendation regarding potential for
decreased clopidogrel effectiveness at this time.
Ticagrelor and CYP3A4 inhibitors Prevents metabolism of ticagrelor via CYP3A4 and might increase the
risk of bleeding
Administration of ticagrelor and strong CYP3A4
inhibitors (e.g., ketoconazole, voriconazole,
clarithromycin, protease inhibitors) is contraindicated
Ticagrelor and CYP3A4 inducers Increases metabolism of ticagrelor via CYP3A4 and might increase
the risk of thrombotic events, including stent thrombosis
Administration of ticagrelor and strong CYP3A4 inducers
(e.g., rifampin, dexamethasone, phenytoin,
carbamazepine) is contraindicated
Ticagrelor and aspirin Unknown; higher aspirin doses might interfere with the antiplatelet
effects of aspirin and increase the risk of thrombotic events
Aspirin dose should not exceed 100 mg/day when used
with ticagrelorContinued on next page
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CCBs. Non-DHP CCBs, described previously, are well-
nown CYP3A4 inhibitors, which might increase
YP3A4-metabolized statin concentrations (atorvastatin,
ovastatin, simvastatin). Additionally, many DHP CCBs
e.g., amlodipine, nifedipine) are competitively metabolized
hrough CYP3A4. Several pharmacokinetic studies of co-
dministration have been performed specifically with dilti-
zem, where the AUC was increased by 4.8-fold with
imvastatin (85) and 3- to 4-fold with lovastatin (86).
dditionally, case reports of rhabdomyolysis have been
ublished with diltiazem and simvastatin (87) as well as
torvastatin (88). In 2011, the FDA, presumably through an
xcess of severe adverse events identified through post-
arket surveillance, recommended a maximum dose of 10
g/day of simvastatin when used with diltiazem or vera-
amil and a maximum of 20 mg/day when used with
mlodipine (84). The significance of the interaction be-
ween amlodipine and simvastatin is not clear. A random-
zed crossover study by Nishio et al. (89) identified a 21%
ncrease in the AUC of simvastatin when co-administered
ith amlodipine. However, in typical drug regimens these
dministrations are separate, with amlodipine given in the
orning and simvastatin at nighttime. Park et al. (90)
dentified no significant change in the AUC of simvastatin
n a crossover study when doses were separated by 4 h.
ecommendations for other CYP3A4-metabolized statins
atorvastatin, lovastatin) are not provided.
OTHERS. Other strong CYP3A4 inhibitors are likely to
increase concentrations of statins metabolized through this
isoenzyme, including atorvastatin, lovastatin, and simvasta-
tin. In particular, the mitigation of muscle-related toxicities
with simvastatin has received a significant amount of atten-
tion from regulatory agencies. In 2011, the FDA commu-
nicated specific dose limitation recommendations for the
use of simvastatin with many CYP3A4 inhibitors (84). In
addition to the recommendations discussed in the preceding
Table 3. Continued
Drug Interaction Mechani
Benzodiazepines and statins Prevents metabolism of oxidatively
(e.g., midazolam, diazepam) via c
through CYP3A4
Benzodiazepines and non-dihydropyridine
calcium channel blockers (e.g.,
diltiazem, verapamil)
Prevents metabolism of oxidatively
(e.g., midazolam, diazepam) via i
Opiates and statins Prevents metabolism of opiates via
through CYP3A4
Opiates and non-dihydropyridine calcium
channel blockers (e.g., diltiazem,
verapamil)
Prevents metabolism of opiates via
ACS  acute coronary syndromes; cath  catheterization; COX  cyclooxygenase; INR  Intern
intervention; PPI proton pump inhibitor.text with regard to fibrates and CCBs, these include amaximum of 20 mg/day of simvastatin when used with
amiodarone or ranolazine and that the use of simvastatin is
contraindicated with itraconazole, ketoconazole, posacona-
zole, erythromycin, clarithromycin, telithromycin, protease
inhibitors, nefazodone, cyclosporine, and danazol. These
recommendations were the result of an analysis of muscle-
related toxicities in the SEARCH (Study of the Effective-
ness of Additional Reductions in Cholesterol and Homo-
cysteine) trial and the FDA internal adverse effects
reporting database (91). The risks associated with these
medications and other CYP3A4 eliminated statins (atorv-
astatin, lovastatin) are less clear, but caution should be
ascribed to the use of high-dose statins and strong CYP3A4
inhibitors. Another communication was provided by the
FDA in 2012, where specific recommendations were pro-
vided for either maximum doses or contraindications for all
CYP3A4-eliminated statins and many drug regimens used
for human immunodeficiency virus or hepatitis C (92). Any
patient with human immunodeficiency virus or hepatitis C
who requires statin-based therapy should have a careful
assessment of the potential for DDI before therapy initia-
tion. The use of non-CYP3A4 eliminated statins (pitavas-
tatin, pravastatin, or rosuvastatin) might be considered
preferential agents in these populations.
Conclusions
The potential for meaningful DDI to occur among inter-
ventional cardiology patients is high and increasing. Such
drug interactions can have devastating consequences, both
in terms of jeopardizing acute procedural success and also
adding increased risk for adverse events over the duration of
treatment. Anticoagulant mixing, for example, might lead
to an increase in bleeding complications related to the
procedure. Furthermore, the variety of potential interactions
with thienopyridine antiplatelets is concerning, because
these drugs are vital to immediate and extended interven-
Recommendation
olized benzodiazepines
itive metabolism
Monitor for over-sedation and respiratory depression;
conscious sedation protocol should consider a less
aggressive titration protocol compared with other
procedural areas
olized benzodiazepines
on of CYP3A4
titive metabolism
ion of CYP3A4
Normalized Ratio; NSAID  nonsteroidal anti-inflammatory drug; PCI  percutaneous coronarysm
metab
ompet
metab
nhibiti
compe
inhibit
ationaltional success. Table 3 summarizes significant DDI that
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catheterization.
Although some DDI have the potential to induce harm in
patients, many others are theoretical or exist only in phar-
macokinetic form, with post-marketing registry reports as
the “clinical evidence” to support the relevance of the issue.
Given the pervasiveness of cardiovascular disease and its
associated pharmacotherapy, more support from regulatory
and scientific bodies is needed to more systematically
examine the clinical relevance of potentially critical DDI
among cardiovascular patients, particularly when such in-
teractions might “innocently” occur because of over-the-
counter medications (e.g., aspirin–NSAIDs or clopidogrel–
omeprazole). It is believable that medication complexity will
increase, and with that in mind, regulatory agencies and
medical societies will need to steadily increase efforts to have
expert-level review and evidence-based reports of clinically
relevant DDI. Regardless of these actions, interventional
providers need to be aware of the potential for DDI and
associated harm in cardiovascular patients and of the appro-
priate action to take, if any, to minimize the potential for
medication-related adverse events.
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